Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prelude TherapeuticsPRLD +0.48%22 Equity-to-Asset is 0.50 as of Mar. 2026, which is 43% below its 10-year median of 0.87. GuruFocus rates PRLD with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Prelude Therapeutics ranks worse than 67.66% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Prelude Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $60.18 Mil. Prelude Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $119.64 Mil.
Therefore, Prelude Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.50.
The historical rank and industry rank for Prelude Therapeutics's Equity-to-Asset or its related term are showing as below:
PRLD'
s Equity-to-Asset Range Over the Past 10 Years
Min: -2.26 Med: 0.87 Max: 0.96
Current: 0.5
During the past 8 years, the highest Equity to Asset Ratio of Prelude Therapeutics was 0.96. The lowest was -2.26. And the median was 0.87.
PRLD's Equity-to-Asset is ranked worse than 67.66% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs PRLD: 0.50
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Prelude Therapeutics Equity-to-Asset Related Terms
Prelude Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Prelude Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRLD vs DMAC, RCKT, CYDY: Equity-to-Asset Comparison
For the Biotechnology subindustry, Prelude Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prelude Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prelude Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Prelude Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Prelude Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prelude Therapeutics (PRLD) has a Equity-to-Asset of 0.50 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Prelude Therapeutics and its competitors. This is 43% below median its historical median of 0.87. According to the industry distribution chart, Prelude Therapeutics ranks #958 out of 1416 companies in the Biotechnology industry, placing it in the top 67.7%.
Is Prelude Therapeutics' Equity-to-Asset too high?
Prelude Therapeutics' current Equity-to-Asset of 0.50 is 43% below median its 10-year median of 0.87. The Biotechnology industry median Equity-to-Asset is 0.68. Prelude Therapeutics' value of 0.50 is 26.5% below this industry median. Based on the distribution chart, Prelude Therapeutics ranks #958 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Prelude Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Prelude Therapeutics' Equity-to-Asset compare to DMAC and RCKT?
According to the Biotechnology industry distribution chart, Prelude Therapeutics ranks #958 out of 1416 companies for Equity-to-Asset. This places Prelude Therapeutics in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Prelude Therapeutics' value of 0.50 is 26.5% below this benchmark. While the company's 10-year median is 0.87 vs. the industry median of 0.68, Prelude Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prelude Therapeutics's current Equity-to-Asset of 0.50 is 26.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Prelude Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prelude Therapeutics's current Equity-to-Asset is 0.50, which is 43% below median its own 10-year median of 0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prelude Therapeutics stock overvalued right now?
Prelude Therapeutics (PRLD) has a current Equity-to-Asset of 0.50. The current Equity-to-Asset is 0.50, which is 43% below median its 10-year median of 0.87 and 26.5% below the Biotechnology industry median of 0.68. Prelude Therapeutics' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Prelude Therapeutics (PRLD), the current Equity-to-Asset is 0.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
22GF Score
Get the complete analysis for PRLD
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRLD has been successfully added to your 
